Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04649359
Recruitment Status : Active, not recruiting
First Posted : December 2, 2020
Last Update Posted : June 8, 2022
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 17, 2022
Estimated Study Completion Date : January 9, 2024